Treatment of IgA nephropathy with eicosapentanoic acid (EPA) : a two-year prospective trial

Bennett, W.M.; Walker, R.G.; Kincaid-Smith, P.

Clinical Nephrology 31(3): 128-131

1989


ISSN/ISBN: 0301-0430
PMID: 2539929
Document Number: 783
Thirty-seven patients with biopsy proven mesangial IgA nephropathy were prospectively allocated to either two years of treatment with eicosapentaenoic acid (EPA) 10 g per day or no treatment. At entry treated and untreated patients with renal dysfunction (Group A) or patients with normal serum creatinine < 0.12 mmol/l (Group B) did not differ in serum creatinine, creatinine clearance, urinary protein excretion, or quantitative urinary red cell counts. Compliance with EPA therapy was excellent as assessed by plasma fatty acid profiles. At the end of the trial creatinine clearance in treated patients had gone from 80 .+-. 16 to 57 .+-. 17 ml/min (p < 0.05) and in untreated patients from 76 .+-. 18 to 55 .+-. 14 (p < 0.05). There were no beneficial effects in either Group A or Group B patients. The only two patients who had improvement in renal function were in the EPA treatment group. Although no side effects of treatment were noted, EPA does not alter the course of established mesangial IgA nephropathy.

Document emailed within 1 workday
Secure & encrypted payments

Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial